Biotech | May 02, 2022
Xcardia announces first-in-human use of its new Xtractor device
The announcement follows FDA 510(k) clearance of device
The announcement follows FDA 510(k) clearance of device
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
It affects up to 10 per cent of women of reproductive age around the world
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Subscribe To Our Newsletter & Stay Updated
